Skip to main content

Table 1 Patient characteristics.

From: A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis

 

700 mg NAC

2800 mg NAC

Number of patients

11

10

Male/female (n)

9/2

7/3

Age

27.0 (21.0 - 35.0)

28.5 (24.0 - 35.0)

Height (cm)

168.0 (163.0 - 178.0)

174.0 (168.0 - 178.0)

Weight (kg)

65.5 (59.0 - 70.40)

64.5 (57.4 - 72.0)

Pseudomonas aeruginosa

4

3

Staphylococcus aureus

1

1

Various bacteria/saprophytic flora

6

6

FEV1 (% pred)

80.6 (55.3 - 90.0)

65.8 (62.9 - 73.4)

FVC (% pred)

82.6 (78.4 - 100.4)

84.8 (79.6 - 91.2)

MEF25-75 (% pred)

41.1 (12.4 - 68.1)

21.6 (19.6 - 27.9)

  1. Data are shown as median (25 - 75%) values